Recent FDA Approvals (through June 2012) related to (GlaxoSmithKline, XenoPort, Roche)
A new indication for gabapentin enacarbil (Horizant, GlaxoSmithKline and XenoPort) extended-release tablets was approved for the management of postherpetic neuralgia in adults.
Pertuzumab (Perjeta, Roche) in combination with Herceptin (trastuzumab) and docetaxel chemotherapy was approved for the treatment of people with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Meningococcal groups C and Y and haemophilus b tetanus toxoid conjugate vaccine (MenHibrix, GlaxoSmithKline) was approved for the prevention of invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MenHibrix is approved for use in children aged 6 weeks through 18 months.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More